Scientists at Michigan Medicine have developed an experimental drug, DT-109, that reversed metabolic dysfunction-associated steatohepatitis (MASH) — a severe form of fatty liver disease — in animal studies by targeting the gut rather than the liver itself. The compound, a glycine-based tripeptide, works by reducing overgrowth of Clostridium perfringens bacteria, lowering ammonia production in the intestines, and reinforcing the gut's protective lining. This prevents harmful microbial substances from traveling to the liver and triggering inflammation. Results were published in The Journal of Clinical Investigation.

The drug showed particularly encouraging results in nonhuman primates, whose gut and liver biology closely mirrors that of humans. Beyond liver disease, prior research suggests DT-109 may also reduce atherosclerotic plaque formation and vascular calcification — pointing to potential cardiovascular benefits. Researchers are also exploring its possible use in inflammatory bowel disease.

Key Takeaways:

• MASH affects approximately 7% of the global population and can progress to cirrhosis, liver cancer, and liver failure
• DT-109 acts primarily in the gastrointestinal tract but produces protective effects in the liver via the gut-liver axis
• Human clinical trials have not yet been conducted — further safety and efficacy studies are needed before patient use

Why it matters: MASH remains notoriously hard to treat, and effective therapies are scarce. DT-109 represents a novel gut-targeted approach that could address both liver and cardiovascular complications — two conditions that frequently co-occur in metabolic disease patients.